Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sean K. Kelley"'
Autor:
Wyne P. Lee, Dong Xie, Ezogelin Oflazoglu, Sean K. Kelley, Iqbal S. Grewal, Ferhan Qureshi, Walter C. Darbonne, Thomas Gelzleichter, Kim Kissler
Publikováno v:
British Journal of Pharmacology. 148:1116-1123
Autor:
Susan M. Chang, Ann Fedoroff, Margaretta Page, Kathleen R. Lamborn, Mary Malec, Ami Kapadia, Michael D. Prados, Dong Xie, Eric C. Burton, Sean K. Kelley, Jane Rabbitt, Nicholas Butowski
Publikováno v:
Neuro-Oncology. 8:67-78
The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with ma
Autor:
Avi Ashkenazi, Andrea Janíková, Myron S Czucman, Ian W. Flinn, Sean K. Kelley, Michelle A. Fanale, John F. Seymour, S. N. Holden, David Belada, Chan Yoon Cheah, Amy V. Kapp, Gordon L Bray
Publikováno v:
The Lancet. Haematology. 2(4)
Summary Background Dulanermin—a non-polyhistidine-tagged soluble recombinant human apoptosis ligand 2 (Apo2L) or tumour-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)—has pro-apoptotic activity in a range of cancers and synergistic pre
Autor:
Robert Mass, Sean K. Kelley, Ted Henderson, George R. Blumenschein, Alan B. Sandler, Roy S. Herbst, Diane D. Liu, Waun Ki Hong, Edward S. Kim, Hai T. Tran, Anne Tsao, Mylene T. Truong, Somasekar Seshagiri, D. Ramies, David H. Johnson, Jack Lee, Eric Mininberg, Dong Xie, David A. Eberhard, David P. Carbone
Publikováno v:
Journal of Clinical Oncology. 23:2544-2555
Purpose Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib HCl (Tarceva, OSI-774; OSI Pharmaceuticals, New York, NY) is a potent, reversible, hi
Autor:
Bert L. Lum, Daniel A. Laheru, Theresa Rogers, N. Senzer, Wells A. Messersmith, Manuel Hidalgo, Sean K. Kelley, David Ramies, Paula Grouleff, Ross C. Donehower
Publikováno v:
Clinical Cancer Research. 10:6522-6527
Purpose: This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinot
Publikováno v:
Toxicological Sciences. 55:478-484
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a highly toxic environmental contaminant that prevents the normal accumulation of vitamin A in liver and causes increased excretion of vitamin A. To determine what alterations in vitamin A metabolism occu
Autor:
Michael H. Green, Sean K. Kelley
Publikováno v:
The Journal of Nutrition. 128:1767-1773
We studied relationships among vitamin A intake, liver levels of vitamin A, plasma retinol concentrations and the irreversible utilization of vitamin A. To supplement existing data, we first used model-based compartmental analysis to determine vitami
Autor:
Sean K. Kelley, Charlotte B. Nilsson, Michael H. Green, Joanne Balrner Green, Helen Håkansson
Publikováno v:
Toxicological Sciences. 44:1-13
Publikováno v:
Cancer chemotherapy and pharmacology. 72(2)
PRO95780, a human monoclonal antibody (mAb) against death receptor 5 (DR5/TRAIL-R2/TNFRSF10B), was developed for the treatment for cancer. Our objective was to characterize pharmacokinetics (PK) in mice, rats, and cynomolgus monkeys and concentration
Autor:
John Edgar Smith, Steven J. Ritter, Sean K. Kelley, Michael H. Green, William R. Adams, Eric M. Schaffer
Publikováno v:
The Journal of Nutritional Biochemistry. 6:689-696
We have reported previously that injecting vitamin A-deficient rats with N-(4-hydroxyphenyl)retinamide causes a significant reduction in the liver retinol-binding protein concentration and a 2 fold rise in the kidney retinol-binding protein concentra